311 related articles for article (PubMed ID: 37479951)
1. Mitochondrial Dysfunction in Cardiotoxicity Induced by BCR-ABL1 Tyrosine Kinase Inhibitors -Underlying Mechanisms, Detection, Potential Therapies.
Sun S; Qin J; Liao W; Gao X; Shang Z; Luo D; Xiong S
Cardiovasc Toxicol; 2023 Aug; 23(7-8):233-254. PubMed ID: 37479951
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.
Singh AP; Umbarkar P; Tousif S; Lal H
Int J Cardiol; 2020 Oct; 316():214-221. PubMed ID: 32470534
[TBL] [Abstract][Full Text] [Related]
4. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
Antoszewska-Smith J; Pawlowska E; Blasiak J
Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.
Slupianek A; Falinski R; Znojek P; Stoklosa T; Flis S; Doneddu V; Pytel D; Synowiec E; Blasiak J; Bellacosa A; Skorski T
Leukemia; 2013 Mar; 27(3):629-34. PubMed ID: 23047475
[TBL] [Abstract][Full Text] [Related]
7. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia.
Brumatti G; Kaloni D; Castro FA; Amarante-Mendes GP
Biochem J; 2023 Jan; 480(2):161-176. PubMed ID: 36719792
[TBL] [Abstract][Full Text] [Related]
8. Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies.
Younes S; Ismail MA; Al-Jurf R; Ziyada A; Nasrallah GK; Abdulrouf PV; Nagy M; Zayed H; Farrell T; Sorio C; Morsi H; Qoronfleh MW; Al-Dewik NI
Hematology; 2023 Dec; 28(1):2196866. PubMed ID: 37078896
[No Abstract] [Full Text] [Related]
9. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
10. BCR/ABL1ΔE7-8-9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Tan Y; Zhang L; Zhu G; Yang Y; Guo W; Chen L; Chang J; Xu Y; Muyey DM; Wang H
Hematol Oncol; 2022 Dec; 40(5):1067-1075. PubMed ID: 35686657
[TBL] [Abstract][Full Text] [Related]
11. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
Jabbour EJ; Sasaki K; Haddad FG; Issa GC; Garcia-Manero G; Kadia TM; Jain N; Yilmaz M; DiNardo CD; Patel KP; Kanagal-Shamanna R; Champlin R; Khouri IF; Dellasala S; Pierce SA; Kantarjian H
Am J Hematol; 2023 Apr; 98(4):658-665. PubMed ID: 36683287
[TBL] [Abstract][Full Text] [Related]
12. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
[TBL] [Abstract][Full Text] [Related]
13. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
Razga F; Jurcek T; Zackova D; Dvorakova D; Toskova M; Jeziskova I; Mayer J; Racil Z
Mol Diagn Ther; 2012 Aug; 16(4):251-9. PubMed ID: 22873741
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
15. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
[TBL] [Abstract][Full Text] [Related]
16. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
17. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
18. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
Lee H; Basso IN; Kim DDH
Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
20. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
